Torrent Pharmaceuticals

Torrent制药公司

, the flagship company of the Torrent Group, announced on Sunday that it will buy a controlling 46.39% stake in

，Torrent集团的旗舰公司，周日宣布将购买46.39%的控股权

JB Chemicals and Pharmaceuticals

JB化学品和制药公司

from global investment firm

来自全球投资公司

KKR

KKR

. The deal values JB Pharma at Rs 25,689 crore on a fully diluted basis. Moreover, after the acquisition, Torrent plans to merge JB Chemicals with itself.

该交易对JB Pharma的估值为2568.9亿卢比（完全稀释后）。此外，在收购完成后，Torrent计划将JB Chemicals与自身合并。

ET had reported of the likely move a day earlier on June 28.

《经济时报》曾在6月28日提前一天报道了这一可能的举动。

'The transaction marks a significant step in Torrent’s ambition to create a future-ready, diversified

“该交易标志着Torrent在实现打造面向未来、多元化发展的雄心方面迈出了重要一步。

healthcare platform

医疗保健平台

combining a deep chronic segment heritage with emerging

结合深厚的慢性病领域传统与新兴技术

international CDMO capabilities

国际CDMO能力

,' said an official memo.

“，”一份官方备忘录说。

According to Torrent, the transaction will be carried out in two phases.

根据Torrent的说法，这笔交易将分两个阶段进行。

In the first phase, Torrent will purchase the 46.39% equity stake from KKR through a Share Purchase Agreement for Rs 11,917 crore, paying Rs 1,600 per share. This will be followed by a mandatory open offer to acquire up to 26% of JB Pharma’s shares from public shareholders at Rs 1,639.18 per share. .

在第一阶段，Torrent将通过股份购买协议以每股1,600卢比的价格，斥资11,917千万卢比从KKR手中购买46.39%的股权。随后，将按照强制性公开要约，以每股1,639.18卢比的价格从公众股东手中收购JB Pharma最多26%的股份。

Live Events

现场活动

Additionally, the has expressed its intention to buy up to 2.80% of shares from certain employees at the same price as KKR.

此外，还表示有意以与KKR相同的价格从某些员工手中购买最多2.80%的股份。

In the second phase, JB Pharma will be merged into Torrent Pharmaceuticals through a scheme of arrangement. As per the approved terms, shareholders holding 100 JB Pharma shares will receive 51 shares of Torrent.

在第二阶段，JB制药公司将通过一项安排计划并入Torrent制药公司。根据批准的条款，持有100股JB制药股票的股东将获得51股Torrent的股票。

'Torrent’s deep India presence and JB Pharma’s fast growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability. This strategic alignment furthers our goal of strengthening our presence in the Indian pharma market, and build a larger diversified global presence.

“Torrent在印度的深厚根基与JB Pharma在印度快速增长的业务相结合，加上CDMO和国际市场的布局，为扩大收入和盈利能力提供了巨大的潜力。这一战略调整进一步推动了我们加强在印度制药市场地位的目标，并打造一个更加多元化和全球化的业务布局。

Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent,' said Samir Mehta Executive chairman, Torrent..

此外，CDMO平台为Torrent提供了新的长期增长途径，Torrent执行主席Samir Mehta表示。

Meanwhile, JB Pharma CEO Nikhil Chopra added that the company has built a strong foundation over the past five years and expressed confidence that joining Torrent will unlock new opportunities to enhance healthcare access across markets.

同时，JB Pharma首席执行官尼基尔·乔普拉补充说，公司过去五年已经打下了坚实的基础，并表示相信加入Torrent将释放新的机会，以增强各市场获得医疗保健的机会。

Strategically, the deal gives Torrent access to JB Pharma’s leading brands in the chronic segment and opens up untapped therapeutic areas like ophthalmology.

从战略上讲，这笔交易使Torrent获得了JB Pharma在慢性病领域的领先品牌，并开辟了眼科等尚未开发的治疗领域。

It is also expected to create operational synergies, strengthen Torrent’s market share in the Indian pharmaceutical market, and diversify its platform into contract development and manufacturing.

它还将创造运营协同效应，加强Torrent在印度医药市场的份额，并将其平台多元化到合同开发和制造领域。

However, the move is yet to get the necessary approvals from the Securities and Exchange Board of India (SEBI), stock exchanges, the Competition Commission of India (CCI), the National Company Law Tribunal (NCLT), and other relevant authorities.

然而，该举措尚未获得印度证券交易委员会 (SEBI)、证券交易所、印度竞争委员会 (CCI)、国家公司法法庭 (NCLT) 和其他相关当局的必要批准。

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)